ATE352311T1 - Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs - Google Patents
Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebsInfo
- Publication number
- ATE352311T1 ATE352311T1 AT01905965T AT01905965T ATE352311T1 AT E352311 T1 ATE352311 T1 AT E352311T1 AT 01905965 T AT01905965 T AT 01905965T AT 01905965 T AT01905965 T AT 01905965T AT E352311 T1 ATE352311 T1 AT E352311T1
- Authority
- AT
- Austria
- Prior art keywords
- breast cancer
- diagnosis
- treatment
- prophylaxis
- membrane proteins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G01N33/57515—
-
- G01N33/57525—
-
- G01N33/57535—
-
- G01N33/57555—
-
- G01N33/57557—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0004576.5A GB0004576D0 (en) | 2000-02-25 | 2000-02-25 | Proteins |
| GB0031341A GB0031341D0 (en) | 2000-12-21 | 2000-12-21 | Protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE352311T1 true ATE352311T1 (de) | 2007-02-15 |
Family
ID=26243736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01905965T ATE352311T1 (de) | 2000-02-25 | 2001-02-21 | Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20030130214A1 (de) |
| EP (2) | EP1257285B1 (de) |
| JP (1) | JP2003524017A (de) |
| KR (1) | KR100740761B1 (de) |
| CN (1) | CN100384875C (de) |
| AT (1) | ATE352311T1 (de) |
| AU (3) | AU2001233913A1 (de) |
| BR (1) | BR0108659A (de) |
| CA (1) | CA2399999A1 (de) |
| DE (1) | DE60126248T2 (de) |
| ES (1) | ES2279801T3 (de) |
| IL (1) | IL151448A0 (de) |
| NZ (1) | NZ520967A (de) |
| WO (2) | WO2001062914A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7054758B2 (en) * | 2001-01-30 | 2006-05-30 | Sciona Limited | Computer-assisted means for assessing lifestyle risk factors |
| GB0125072D0 (en) * | 2001-10-18 | 2001-12-12 | Oxford Glycosciences Uk Ltd | Protein |
| AU2003209459A1 (en) * | 2002-03-06 | 2003-09-16 | Hybrigenics | Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11 |
| US20040033530A1 (en) * | 2002-04-08 | 2004-02-19 | Awrey Donald E. | High throughput purification, characterization and identification of recombinant proteins |
| GB0208331D0 (en) * | 2002-04-11 | 2002-05-22 | Oxford Glycosciences Uk Ltd | Proteins |
| FR2846426B1 (fr) * | 2002-10-28 | 2004-12-10 | Bio Merieux | Procede de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie |
| KR20050092366A (ko) * | 2002-12-06 | 2005-09-21 | 싱가포르 제너럴 하스피털 피티이 엘티디. | 펩티드, 이에 대한 항체, 및 중추 신경계 손상의 치료에있어서의 이의 용도 |
| WO2005029083A1 (en) * | 2003-09-22 | 2005-03-31 | Green Peptide Co., Ltd. | Prognosis in cancer patients vaccinated with a cancer antigen peptide-associated agent |
| EP1693069B1 (de) | 2003-10-10 | 2013-07-24 | Chugai Seiyaku Kabushiki Kaisha | Mittel zur behandlung von soliden tumoren |
| JP2007520217A (ja) * | 2004-01-27 | 2007-07-26 | コンピュゲン ユーエスエイ,インク. | 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法 |
| KR100763902B1 (ko) * | 2004-02-20 | 2007-10-05 | 삼성전자주식회사 | 유방암 특이적 단백질, 그를 코딩하는 유전자, 및 상기단백질 또는 유전자를 이용한 유방암의 진단 방법 |
| WO2008104803A2 (en) * | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| KR101398079B1 (ko) | 2011-10-10 | 2014-05-27 | 재단법인 의약바이오컨버젼스연구단 | 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법 |
| CN104447975A (zh) * | 2014-11-18 | 2015-03-25 | 深圳市人口和计划生育科学研究所 | 一种提取人肿瘤细胞膜蛋白的方法 |
| WO2017011375A1 (en) * | 2015-07-10 | 2017-01-19 | University Of Iowa Reseaarch Foundation | Bst-2 as a therapeutic target and a predictive/prognostic bio-signature for breast cancer growth and metastasis |
| EP4467565A3 (de) | 2016-12-21 | 2025-03-12 | Amgen Inc. | Anti-tnf-alpha-antikörperformulierungen |
| KR102312897B1 (ko) * | 2021-02-26 | 2021-10-15 | 에스케이바이오사이언스(주) | 목적 단백질의 고수율 정제방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0929575A4 (de) * | 1996-08-23 | 2004-09-08 | Human Genome Sciences Inc | Neue menschliche wachstumsfaktoren. |
| DE19813839A1 (de) * | 1998-03-20 | 1999-09-23 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Brusttumorgewebe |
| CA2380873A1 (en) * | 1999-06-30 | 2001-01-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
-
2001
- 2001-02-21 WO PCT/GB2001/000729 patent/WO2001062914A1/en not_active Ceased
- 2001-02-21 IL IL15144801A patent/IL151448A0/xx unknown
- 2001-02-21 ES ES01905965T patent/ES2279801T3/es not_active Expired - Lifetime
- 2001-02-21 CN CNB018084885A patent/CN100384875C/zh not_active Expired - Fee Related
- 2001-02-21 EP EP01905965A patent/EP1257285B1/de not_active Expired - Lifetime
- 2001-02-21 DE DE60126248T patent/DE60126248T2/de not_active Expired - Fee Related
- 2001-02-21 AU AU2001233913A patent/AU2001233913A1/en not_active Abandoned
- 2001-02-21 KR KR1020027011130A patent/KR100740761B1/ko not_active Expired - Fee Related
- 2001-02-21 CA CA002399999A patent/CA2399999A1/en not_active Abandoned
- 2001-02-21 WO PCT/GB2001/000748 patent/WO2001062784A2/en not_active Ceased
- 2001-02-21 AU AU2001233929A patent/AU2001233929C1/en not_active Ceased
- 2001-02-21 AU AU3392901A patent/AU3392901A/xx active Pending
- 2001-02-21 EP EP01905949A patent/EP1259604A1/de not_active Withdrawn
- 2001-02-21 AT AT01905965T patent/ATE352311T1/de not_active IP Right Cessation
- 2001-02-21 NZ NZ520967A patent/NZ520967A/en unknown
- 2001-02-21 BR BR0108659-6A patent/BR0108659A/pt not_active IP Right Cessation
- 2001-02-21 JP JP2001562565A patent/JP2003524017A/ja active Pending
- 2001-02-23 US US09/791,392 patent/US20030130214A1/en not_active Abandoned
-
2002
- 2002-08-23 US US10/227,616 patent/US20030099662A1/en not_active Abandoned
-
2006
- 2006-08-24 US US11/509,841 patent/US20070212368A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR0108659A (pt) | 2002-11-05 |
| US20030099662A1 (en) | 2003-05-29 |
| DE60126248D1 (de) | 2007-03-15 |
| AU3392901A (en) | 2001-09-03 |
| AU2001233929C1 (en) | 2006-03-02 |
| EP1257285A2 (de) | 2002-11-20 |
| HK1056692A1 (zh) | 2004-02-27 |
| KR20030007440A (ko) | 2003-01-23 |
| KR100740761B1 (ko) | 2007-07-19 |
| NZ520967A (en) | 2004-04-30 |
| JP2003524017A (ja) | 2003-08-12 |
| AU2001233913A1 (en) | 2001-09-03 |
| WO2001062784A3 (en) | 2002-01-31 |
| DE60126248T2 (de) | 2007-07-05 |
| CN100384875C (zh) | 2008-04-30 |
| WO2001062914A1 (en) | 2001-08-30 |
| CA2399999A1 (en) | 2001-08-30 |
| EP1259604A1 (de) | 2002-11-27 |
| AU2001233929B2 (en) | 2005-09-08 |
| US20030130214A1 (en) | 2003-07-10 |
| EP1257285B1 (de) | 2007-01-24 |
| CN1426307A (zh) | 2003-06-25 |
| IL151448A0 (en) | 2003-04-10 |
| ES2279801T3 (es) | 2007-09-01 |
| US20070212368A1 (en) | 2007-09-13 |
| WO2001062784A2 (en) | 2001-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE352311T1 (de) | Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs | |
| ATE453653T1 (de) | Platinkomplexe zur behandlung von tumoren | |
| ATE397754T1 (de) | Verwendung von sc6 für die diagnose und behandlung von bustkarzinom | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| EP1363920A4 (de) | Modifizierte psma-liganden und deren verwendung | |
| DE60108230D1 (de) | Vorrichtung für diagnose und behandlung von arrhytmien | |
| ATE325343T1 (de) | Diagnose und behandlung von arthritischen erkrankungen | |
| DE602004017736D1 (de) | Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| ATE419516T1 (de) | Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc) | |
| NO20055741L (no) | Nye kjemiske forbindelser | |
| DE60026150D1 (de) | Diagnostika und therapeutika für osteoporose | |
| ATE338142T1 (de) | Methoden zur diagnose und behandlung von herzkrankheiten | |
| ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| DE602004029061D1 (de) | Zusammensetzungen, reagenzien, kits und verfahren für die diagnose und behandlung von fettleibigkeit und/oder diabetes | |
| WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
| ATE306668T1 (de) | Diagnose von brustkrebs unter verwendung von bcmp-7 als marker | |
| ATE393785T1 (de) | Glykopeptide, deren herstellung und verwendung in der diagnose oder behandlung von multipler sklerose | |
| DE60213365D1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| ATE546154T1 (de) | Anti-angiogenetisches mittel und seine verwendung bei der krebsbehandlung | |
| ATE390435T1 (de) | Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie | |
| EA200600012A1 (ru) | Полиморфизм человеческого гена nbs1, полезный для диагностики наследственной предрасположенности к раку | |
| DE69931644D1 (de) | Verfahren zur diagnose, feststellung, einstufung, darstellung sowie behandlung gynäkologischer krebserkrankungen | |
| ATE423780T1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| DE60020970D1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |